MP28-11 USE OF 5A-REDUCTASE INHIBITORS IS ASSOCIATED WITH LOWER RISK OF INFECTION WITH SARS-COV-2 (2021)

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Epidemiology & Evaluation (MP28)1 Sep 2021MP28-11 USE OF 5A-REDUCTASE INHIBITORS IS ASSOCIATED WITH LOWER RISK OF INFECTION WITH SARS-COV-2 Madison Lyon, Jianbo Li, Alex Milinovich, Nima Sharifi, and Eric A. Klein Madison LyonMadison Lyon , Jianbo LiJianbo Li , Alex MilinovichAlex Milinovich , Nima SharifiNima Sharifi , and Eric A. KleinEric A. Klein View All Author Informationhttps://doi.org/10.1097/JU.0000000000002025.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The TMPRSS protein serves as a host co-receptor for the SARS-CoV-2 virus that causes COVID-19 and is present in both prostate and lung tissue. This protein is known to be androgen regulated in the prostate, however, there is conflicting data on whether it is also androgen regulated in the lung, an important site for COVID-19 infection. Two randomized controlled trials have shown 5a-reductase inhibitors (5aRI) reduced the severity of COVID-19 symptoms in infected men, and reduced the likelihood of hospitalization. In the present study, we assessed the effect of 5aRI use on risk of community acquired COVID-19 infection. METHODS: All men without prostate cancer included in an institutional prospective registry of all patients tested for SARS-CoV-2 between March 8, 2020 and February 15, 2021 were included. Patients in the 5ARI cohort were matched at a 1:1 ratio to those not on 5ARI based on demographics and comorbidities that are known to increase the risk of infection. Exact matching was performed on race, diabetes, hypertension, coronary artery disease and immune suppressive disease. The main outcome measures were the effect of 5aRI use on the rate of SARS-Cov-2 positivity and disease severity as measured by hospitalization, ICU admission, and death. RESULTS: 60,474 males without prostate cancer diagnosis were initially selected, of which 1,079 were on 5ARI (1.8%). The matched cohorts included 1,075 on 5ARI and 1,075 non-5ARI, aged 21 to 99 years (Fig. 1). Of all the demographics and risk factors none were significantly different between the 5ARI groups in the matched cohorts. Risk for SARS-CoV-2 was significantly lower in the 5ARI group (OR 0.82, 95% CI 0.69-0.97, p=0.024, Table). Multivariable logistic regression analysis based on the entire data before matching reached the same conclusion. CONCLUSIONS: Men without prostate cancer taking a 5aRI are at lower risk for community acquired COVID-19 infection. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e485-e485 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.Metrics Author Information Madison Lyon More articles by this author Jianbo Li More articles by this author Alex Milinovich More articles by this author Nima Sharifi More articles by this author Eric A. Klein More articles by this author Expand All Advertisement PDF downloadLoading ...